Replies to post #2070 on Idenix Pharmaceuticals (IDIX)

[DewDiligence]

Puginier replaces Ebeling as one of NVS’ two directors on
IDIX’s BoD. This was expected inasmuch as Ebeling was
recently demoted from head of NVS’ pharma division to
head of its consumer division (#msg-23784225).

http://biz.yahoo.com/e/071129/idix8-k.html

>>
On November 23, 2007, Novartis Pharma AG ("Novartis") nominated Emmanuel Puginier, M.D. as one of its two designees to the Board of Directors (the "Board") of Idenix Pharmaceuticals, Inc. (the "Company"). Previously, Mr. Thomas Ebeling and Mr. Robert Pelzer had served as Novartis' two designees to the Company's Board. Mr. Pelzer will remain on the Board as a Novartis designee.

Dr. Puginier, who currently holds the position of Global Head of Marketing and Sales General Medicines at Novartis, is expected to serve on the Compensation Committee of the Board. Mr. Pelzer will continue to serve as a non-voting observer to each of the Audit Committee and Nominating and Corporate Governance Committee of the Board. Neither Dr. Puginier nor Mr. Pelzer will receive any compensation for their services as directors on the Board.
<<